TISIDB

Summary
Symbol	ITGB3
Name	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
Aliases	CD61; GPIIIa; platelet glycoprotein IIIa; GP3A; platelet membrane glycoprotein IIIa; CD antigen CD61; Integr ......
Chromosomal Location	17q21.32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein Cell projection, lamellipodium membrane Cell junction, focal adhesion
Domain	PF07974 EGF-like domain PF08725 Integrin beta cytoplasmic domain PF07965 Integrin beta tail domain PF00362 Integrin beta chain VWA domain PF17205 Integrin plexin domain
Function	Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (By similarity). ITGAV:ITGB3 binds to fractalkine (CX3CL1) and acts as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415, PubMed:24789099). ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778). ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling (PubMed:18441324). ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling (PubMed:28302677). ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:19578119). ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling (PubMed:28873464). ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling (PubMed:29030430). ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGAV:ITGB3 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887). ; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Herpes virus 8/HHV-8. ; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Coxsackievirus A9. ; FUNCTION: (Microbial infection) Acts as a receptor for Hantaan virus. ; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Cytomegalovirus/HHV-5. ; FUNCTION: (Microbial infection) Integrin ITGA5:ITGB3 acts as a receptor for Human metapneumovirus. ; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts aP05556s a receptor for Human parechovirus 1. ; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for West nile virus. ; FUNCTION: (Microbial infection) In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

> Gene Ontology [ TOP ]
Biological Process	GO:0001525 angiogenesis GO:0001667 ameboidal-type cell migration GO:0001704 formation of primary germ layer GO:0001707 mesoderm formation GO:0001894 tissue homeostasis GO:0001935 endothelial cell proliferation GO:0001936 regulation of endothelial cell proliferation GO:0001938 positive regulation of endothelial cell proliferation GO:0002576 platelet degranulation GO:0006869 lipid transport GO:0006887 exocytosis GO:0007044 cell-substrate junction assembly GO:0007160 cell-matrix adhesion GO:0007229 integrin-mediated signaling pathway GO:0007369 gastrulation GO:0007498 mesoderm development GO:0007596 blood coagulation GO:0007599 hemostasis GO:0010594 regulation of endothelial cell migration GO:0010595 positive regulation of endothelial cell migration GO:0010631 epithelial cell migration GO:0010632 regulation of epithelial cell migration GO:0010634 positive regulation of epithelial cell migration GO:0010742 macrophage derived foam cell differentiation GO:0010743 regulation of macrophage derived foam cell differentiation GO:0010745 negative regulation of macrophage derived foam cell differentiation GO:0010869 regulation of receptor biosynthetic process GO:0010871 negative regulation of receptor biosynthetic process GO:0010876 lipid localization GO:0010883 regulation of lipid storage GO:0010888 negative regulation of lipid storage GO:0014812 muscle cell migration GO:0014909 smooth muscle cell migration GO:0016049 cell growth GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0019058 viral life cycle GO:0019915 lipid storage GO:0030168 platelet activation GO:0030198 extracellular matrix organization GO:0030260 entry into host cell GO:0030335 positive regulation of cell migration GO:0030947 regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0031589 cell-substrate adhesion GO:0032147 activation of protein kinase activity GO:0032368 regulation of lipid transport GO:0032369 negative regulation of lipid transport GO:0032799 low-density lipoprotein receptor particle metabolic process GO:0032800 receptor biosynthetic process GO:0032844 regulation of homeostatic process GO:0033627 cell adhesion mediated by integrin GO:0033674 positive regulation of kinase activity GO:0034103 regulation of tissue remodeling GO:0034109 homotypic cell-cell adhesion GO:0034113 heterotypic cell-cell adhesion GO:0034329 cell junction assembly GO:0034330 cell junction organization GO:0034446 substrate adhesion-dependent cell spreading GO:0038027 apolipoprotein A-I-mediated signaling pathway GO:0040017 positive regulation of locomotion GO:0042157 lipoprotein metabolic process GO:0043062 extracellular structure organization GO:0043112 receptor metabolic process GO:0043542 endothelial cell migration GO:0044409 entry into host GO:0045055 regulated exocytosis GO:0045124 regulation of bone resorption GO:0045453 bone resorption GO:0045713 low-density lipoprotein particle receptor biosynthetic process GO:0045714 regulation of low-density lipoprotein particle receptor biosynthetic process GO:0045715 negative regulation of low-density lipoprotein particle receptor biosynthetic process GO:0045860 positive regulation of protein kinase activity GO:0046718 viral entry into host cell GO:0046849 bone remodeling GO:0046850 regulation of bone remodeling GO:0048010 vascular endothelial growth factor receptor signaling pathway GO:0048332 mesoderm morphogenesis GO:0048333 mesodermal cell differentiation GO:0048514 blood vessel morphogenesis GO:0048771 tissue remodeling GO:0048871 multicellular organismal homeostasis GO:0050673 epithelial cell proliferation GO:0050678 regulation of epithelial cell proliferation GO:0050679 positive regulation of epithelial cell proliferation GO:0050730 regulation of peptidyl-tyrosine phosphorylation GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation GO:0050746 regulation of lipoprotein metabolic process GO:0050748 negative regulation of lipoprotein metabolic process GO:0050817 coagulation GO:0050878 regulation of body fluid levels GO:0050900 leukocyte migration GO:0050919 negative chemotaxis GO:0051051 negative regulation of transport GO:0051235 maintenance of location GO:0051272 positive regulation of cellular component movement GO:0051701 interaction with host GO:0051806 entry into cell of other organism involved in symbiotic interaction GO:0051828 entry into other organism involved in symbiotic interaction GO:0060055 angiogenesis involved in wound healing GO:0060249 anatomical structure homeostasis GO:0070527 platelet aggregation GO:0090077 foam cell differentiation GO:0090130 tissue migration GO:0090132 epithelium migration GO:0090287 regulation of cellular response to growth factor stimulus GO:2000147 positive regulation of cell motility
Molecular Function	GO:0001618 virus receptor activity GO:0001968 fibronectin binding GO:0002020 protease binding GO:0003756 protein disulfide isomerase activity GO:0005126 cytokine receptor binding GO:0005161 platelet-derived growth factor receptor binding GO:0005172 vascular endothelial growth factor receptor binding GO:0005520 insulin-like growth factor binding GO:0015026 coreceptor activity GO:0016853 isomerase activity GO:0016860 intramolecular oxidoreductase activity GO:0016864 intramolecular oxidoreductase activity, transposing S-S bonds GO:0017134 fibroblast growth factor binding GO:0019838 growth factor binding GO:0019955 cytokine binding GO:0019956 chemokine binding GO:0019960 C-X3-C chemokine binding GO:0031994 insulin-like growth factor I binding GO:0038132 neuregulin binding GO:0043184 vascular endothelial growth factor receptor 2 binding GO:0050839 cell adhesion molecule binding GO:0050840 extracellular matrix binding GO:0070851 growth factor receptor binding
Cellular Component	GO:0001726 ruffle GO:0005902 microvillus GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0008305 integrin complex GO:0030027 lamellipodium GO:0030055 cell-substrate junction GO:0030141 secretory granule GO:0030175 filopodium GO:0030659 cytoplasmic vesicle membrane GO:0030667 secretory granule membrane GO:0031091 platelet alpha granule GO:0031092 platelet alpha granule membrane GO:0031252 cell leading edge GO:0031253 cell projection membrane GO:0031256 leading edge membrane GO:0031258 lamellipodium membrane GO:0031527 filopodium membrane GO:0031528 microvillus membrane GO:0032587 ruffle membrane GO:0034683 integrin alphav-beta3 complex GO:0035867 alphav-beta3 integrin-IGF-1-IGF1R complex GO:0042470 melanosome GO:0043235 receptor complex GO:0048770 pigment granule GO:0071062 alphav-beta3 integrin-vitronectin complex GO:0098636 protein complex involved in cell adhesion GO:0098802 plasma membrane receptor complex GO:0098858 actin-based cell projection GO:0099503 secretory vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04015 Rap1 signaling pathway hsa04145 Phagosome hsa04151 PI3K-Akt signaling pathway hsa04380 Osteoclast differentiation hsa04510 Focal adhesion hsa04512 ECM-receptor interaction hsa04611 Platelet activation hsa04640 Hematopoietic cell lineage hsa04810 Regulation of actin cytoskeleton hsa04919 Thyroid hormone signaling pathway
Reactome	R-HSA-170984: ARMS-mediated activation R-HSA-422475: Axon guidance R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-186763: Downstream signal transduction R-HSA-3000178: ECM proteoglycans R-HSA-1566948: Elastic fibre formation R-HSA-1474244: Extracellular matrix organization R-HSA-2871796: FCERI mediated MAPK activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-170968: Frs2-mediated activation R-HSA-179812: GRB2 events in EGFR signaling R-HSA-354194: GRB2 R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-109582: Hemostasis R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-354192: Integrin alphaIIb beta3 signaling R-HSA-216083: Integrin cell surface interactions R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-373760: L1CAM interactions R-HSA-5674135: MAP2K and MAPK activation R-HSA-5683057: MAPK family signaling cascades R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-2129379: Molecules associated with elastic fibres R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-3000171: Non-integrin membrane-ECM interactions R-HSA-6802957: Oncogenic MAPK signaling R-HSA-210990: PECAM1 interactions R-HSA-6802955: Paradoxical activation of RAF signaling by kinase inactive BRAF R-HSA-76009: Platelet Aggregation (Plug Formation) R-HSA-76002: Platelet activation, signaling and aggregation R-HSA-114608: Platelet degranulation R-HSA-169893: Prolonged ERK activation events R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-76005: Response to elevated platelet cytosolic Ca2+ R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-445144: Signal transduction by L1 R-HSA-6802952: Signaling by BRAF and RAF fusions R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-186797: Signaling by PDGF R-HSA-6802949: Signaling by RAS mutants R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-6802948: Signaling by high-kinase activity BRAF mutants R-HSA-6802946: Signaling by moderate kinase activity BRAF mutants R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-3000170: Syndecan interactions R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation R-HSA-372708: p130Cas linkage to MAPK signaling for integrins

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04015 Rap1 signaling pathway
hsa04145 Phagosome
hsa04151 PI3K-Akt signaling pathway
hsa04380 Osteoclast differentiation
hsa04510 Focal adhesion
hsa04512 ECM-receptor interaction
hsa04611 Platelet activation
hsa04640 Hematopoietic cell lineage
hsa04810 Regulation of actin cytoskeleton
hsa04919 Thyroid hormone signaling pathway

Reactome

R-HSA-170984: ARMS-mediated activation
R-HSA-422475: Axon guidance
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-3000178: ECM proteoglycans
R-HSA-1566948: Elastic fibre formation
R-HSA-1474244: Extracellular matrix organization
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-354194: GRB2
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-354192: Integrin alphaIIb beta3 signaling
R-HSA-216083: Integrin cell surface interactions
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-373760: L1CAM interactions
R-HSA-5674135: MAP2K and MAPK activation
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-2129379: Molecules associated with elastic fibres
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-3000171: Non-integrin membrane-ECM interactions
R-HSA-6802957: Oncogenic MAPK signaling
R-HSA-210990: PECAM1 interactions
R-HSA-6802955: Paradoxical activation of RAF signaling by kinase inactive BRAF
R-HSA-76009: Platelet Aggregation (Plug Formation)
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-445144: Signal transduction by L1
R-HSA-6802952: Signaling by BRAF and RAF fusions
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-6802949: Signaling by RAS mutants
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-6802948: Signaling by high-kinase activity BRAF mutants
R-HSA-6802946: Signaling by moderate kinase activity BRAF mutants
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-3000170: Syndecan interactions
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
R-HSA-372708: p130Cas linkage to MAPK signaling for integrins

Summary
Symbol	ITGB3
Name	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
Aliases	CD61; GPIIIa; platelet glycoprotein IIIa; GP3A; platelet membrane glycoprotein IIIa; CD antigen CD61; Integr ......
Chromosomal Location	17q21.32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ITGB3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between ITGB3 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
27216180	Melanoma; Breast Carcinoma	Promote immunity (infiltration)	We hypothesized that integrin β3 could affect tumor immunity and evaluated tumors in mice with deletion of integrin β3 in macrophage lineage cells (β3KOM). β3KOM mice had increased melanoma and breast cancer growth with increased tumor-promoting M2 macrophages and decreased CD8(+) T cells.

Summary
Symbol	ITGB3
Name	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
Aliases	CD61; GPIIIa; platelet glycoprotein IIIa; GP3A; platelet membrane glycoprotein IIIa; CD antigen CD61; Integr ......
Chromosomal Location	17q21.32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ITGB3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ITGB3
Name	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
Aliases	CD61; GPIIIa; platelet glycoprotein IIIa; GP3A; platelet membrane glycoprotein IIIa; CD antigen CD61; Integr ......
Chromosomal Location	17q21.32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ITGB3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.046	0.957
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.737	0.711
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.446	0.758
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.457	0.347
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.506	0.79
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.395	0.868
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.1	0.899
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.737	0.687
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.778	0.668
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.721	0.581
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.508	0.393
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.602	0.00141

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ITGB3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	0	14.3	0.196
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	20	0	20	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	ITGB3
Name	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
Aliases	CD61; GPIIIa; platelet glycoprotein IIIa; GP3A; platelet membrane glycoprotein IIIa; CD antigen CD61; Integr ......
Chromosomal Location	17q21.32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITGB3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ITGB3
Name	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
Aliases	CD61; GPIIIa; platelet glycoprotein IIIa; GP3A; platelet membrane glycoprotein IIIa; CD antigen CD61; Integr ......
Chromosomal Location	17q21.32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITGB3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITGB3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ITGB3
Name	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
Aliases	CD61; GPIIIa; platelet glycoprotein IIIa; GP3A; platelet membrane glycoprotein IIIa; CD antigen CD61; Integr ......
Chromosomal Location	17q21.32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITGB3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ITGB3
Name	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
Aliases	CD61; GPIIIa; platelet glycoprotein IIIa; GP3A; platelet membrane glycoprotein IIIa; CD antigen CD61; Integr ......
Chromosomal Location	17q21.32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ITGB3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ITGB3
Name	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
Aliases	CD61; GPIIIa; platelet glycoprotein IIIa; GP3A; platelet membrane glycoprotein IIIa; CD antigen CD61; Integr ......
Chromosomal Location	17q21.32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ITGB3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ITGB3
Name	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
Aliases	CD61; GPIIIa; platelet glycoprotein IIIa; GP3A; platelet membrane glycoprotein IIIa; CD antigen CD61; Integr ......
Chromosomal Location	17q21.32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ITGB3 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting ITGB3.

ID	Name	Drug Type	Targets	#Targets
DB00054	Abciximab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	14
DB00063	Eptifibatide	Biotech	ITGB3	1
DB00098	Antithymocyte immunoglobulin (rabbit)	Biotech	CD1A, CD4, CD86, FCGR2B, ITGAL, ITGAV, ITGB1, ITGB3, MR1	9
DB00775	Tirofiban	Small Molecule	ITGA2B, ITGB3	2
DB02709	Resveratrol	Small Molecule	AHR, AKT1, ALOX15, ALOX5, APP, CBR1, CLEC14A, CSNK2A1, ESR1, ITGA5 ......	25
DB04863	Lefradafiban	Small Molecule	ITGA2B, ITGB3	2
DB05787	LM-609	Biotech	ITGB3	1
DB06472	Fradafiban	Small Molecule	ITGA2B, ITGB3	2

Browse ITGB3